Aumentare lo sviluppo industriale delle vescicole extracellulari (EVs) CD99-null come strumento terapeutico utilizzando il sarcoma di Ewing come prototipo

Title

Code

START

Type

Sperimentale

Start Year

2024

Status

In Corso

Principal Investigator

051-6366652

marco.gambarotti@ior.it

Gambarotti Marco, MD

Head

Anatomy and Pathological Histology

Operational unit that carry out the study

departmental simple unit

Anatomia e istologia patologica

Head

Gambarotti Marco, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. START

Monday 18 March 2024, 13:46

PG0004318_2024_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Aumentare lo sviluppo industriale delle vescicole extracellulari (EVs) CD99-null come strumento terapeutico utilizzando il sarcoma di Ewing come prototipo

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Aumentare lo sviluppo industriale delle vescicole extracellulari (EVs) CD99-null come strumento terapeutico utilizzando il sarcoma di Ewing come prototipo

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in